Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

Investing.com -- Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares gained 2.6% after the biopharmaceutical company provided an update on the U.S. launch of its newly approved drug VYKAT XR and reported ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical and clinical-stage ...

Pipeline programs: Design continues to progress preclinical activities for its myotonic dystrophy type-1 (DM1) program toward the selection of a development candidate later in 2025. In Huntington's ...

Capnia Inc stock has reached a new 52-week high, with shares trading at $74.0, marking a significant milestone for the company.... Tuesday, Piper Sandler reiterated an Overweight rating and a $93. ...

The institute, set to become a national hub for the animation, visual effects, gaming, comics, and extended reality (AVGC-XR) sector, has already commenced work and has aligned with a few tech and ...

The annual developer conference, set for May 20-21 in Mountain View, California, is expected to cover familiar ground, Android, artificial intelligence, and design, but with some potentially ...

MPR, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient outcomes.